Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study

Launched by INSTITUT CURIE · Oct 4, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the quality of life and experiences of patients with uveal melanoma after their treatment. Uveal melanoma is a type of eye cancer, and this study aims to gather information during the surveillance phase, which is the period when doctors closely monitor patients for any signs of the cancer returning. Participants will have previously received treatment for their cancer and will be monitored based on their individual risk of recurrence. The study looks at how satisfied patients are with the communication they receive from their doctors, as well as their feelings about anxiety, fear of recurrence, and overall health status during the first year of surveillance.

To be eligible for the trial, participants must be at least 18 years old, have been diagnosed with non-metastatic uveal melanoma, and have completed their initial treatment at least six months prior. They will fill out questionnaires about their quality of life at two different times during the year. A smaller group may also take part in interviews to share their experiences in more detail. The researchers will compare results between patients at high risk of the cancer coming back and those at low risk to see how their experiences differ. This study is not yet recruiting participants, but it aims to provide valuable insights into how to better support patients during their follow-up care.

Gender

ALL

Eligibility criteria

• • Patient aged 18 years or older.
• • Diagnosed with a non-metastatic uveal melanoma
• • Completion of primary tumour treatment ≥ 6 months (+/- two months).
• • Able to respect scheduled visits.
• • Able to read and understand the language of the questionnaires.
• Two groups of patients will be identified:
• 1. Patients with non-metastatic uveal melanoma at high risk for metastatic relapse defined as:
• • T2b/c/d or ≥ T3,
• • or anomaly on either chromosome 3 or chromosome 8, found by CGH array or sequencing.
• 2. Patients with non-metastatic uveal melanoma at low risk of recurrence defined as:
• • T2a,
• • and/or no alteration of chromosome 3 or chromosome 8 has been found.